Close Menu

phase I clinical study

Personalis plans to develop a companion diagnostic to MapKure's BRAF inhibitor, BGB-3245, once biomarkers have been identified in the study.

Strata will use its StrataNGS profiling test to identify patients with advanced solid tumors harboring KRAS G12C mutations for enrollment into Mirati's KRYSTAL-1 trial.

Natera's Signatera test will be used to select and monitor eligible patients with KRAS-mutant tumors who have molecular residual disease after surgery.

Roche is developing an immunohistochemnistry assay for Pierre Fabre's oncology drug candidate, an antibody drug conjugate targeting insulin-like growth factor 1 receptor.